Genetically engineered bacterial‐like particles induced specific cellular and humoral immunity as effective tick‐borne encephalitis virus vaccine

Abstract

Abstract Tick‐borne encephalitis (TBE) is a natural focal disease with fatal encephalitis induced by tick‐borne encephalitis virus (TBEV), seriously threatening human and public health. Protection of TBE depends on vaccination with inactivated vaccine, which requires high cost and multiple immunizations. Here, we construct genetically engineered bacterial‐like particles (BLPs) as an effective TBEV vaccine with simplified immunizations and improved immune efficacy. The TBEV BLPs involve the combination of the gram‐positive enhancer matrix from Lactococcus lactis, and TBEV envelope (E) protein expressed by genetically engineered recombinant baculovirus. The prepared TBEV BLPs can effectively stimulate the activation of dendritic cells to present the TBEV E proteins to T and B cells, leading to strong and durable cellular and humoral immune responses in mice. Surprisingly, the serum levels of specific IgG antibodies in mice remain about 106 at 6 months after the secondary immunization. Overall, the TBEV BLPs can be used as a potent vaccine candidate, laying the foundation for developing novel TBEV genetically engineered vaccines.

Keywords

• bacterial‐like particles
• envelope protein
• genetically engineered vaccines
• gram‐positive enhancer matrix
• tick‐borne encephalitis virus